{
    "name": "sodium polystyrene sulfonate",
    "comment": "Rx",
    "other_names": [
        "SPS",
        "Kayexalate",
        "Kionex",
        "Kalexate"
    ],
    "classes": [
        "Potassium Binders"
    ],
    "source": "https://reference.medscape.com/drug/sps-kayexalate-sodium-polystyrene-sulfonate-342837",
    "pregnancy": {
        "common": [
            "Not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to polystyrene sulfonate resins",
                "Hypokalemia",
                "Obstructive bowel disease",
                "Neonates with reduced gut motility (postoperative or drug-induced), oral administration",
                "Rectal administration of suspension with sorbitol in neonates, particularly in premature infants"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in congestive heart failure, severe hypertension, marked edema (due to sodium content; 1 g contains 100 mg of sodium, 1/3 of which is delivered to body)",
                "Best when used in non-life-threatening hyperkalemia",
                "Monitor electrolytes",
                "Large doses may result in fecal impaction, especially in the elderly",
                "Hypokalemia may occur monitor serum potassium frequently within each 24 hr period; ECG monitoring may be appropriate in some patients; cation exchange resins may also affect concentrations of other cations, including calcium and magnesium",
                "In severe hyperkalemia, consider more immediate treatment modalities (eg, dialysis, IV calcium, bicarbonate, glucose, and insulin)",
                "Products can contain as much as 20 g of sorbitol per 15 g of sodium polystyrene",
                "Use caution with dosage forms containing propylene glycol; large amounts are potentially toxic; associated with hyperosmolality, seizures, lactic acidosis, and respiratory depression",
                "Do not use in patients who do not have normal bowel function, including postoperative patients who have not had a bowel movement since operation' avoid use in postoperative patients at risk of constipation or impaction until normal bowel function resumes; discontinue use if constipation occurs",
                "Do not mix PO dose with banana or orange juice (potassium-rich)",
                "If there is clinically significant constipation, discontinue until normal bowel motion; do not use magnesium-containing laxatives or sorbitol",
                "In children and neonates rectal administration, excessive dosage or inadequate dilution could result in impaction of resin",
                "Premature and low-birth-weight infants: Risk of digestive hemorrhage or colonic necrosis",
                "Enema may reduce serum concentrations faster than oral administration but oral route will achieve greater reduction over several hours",
                "Risk of colonic necrosis and other serious GI adverse events (eg, bleeding, ischemic colitis, perforation), most frequently with concomitant use of sorbitol",
                "Concomitant administration of sorbitol is not recommended",
                "Risk factors for GI adverse events include prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency or failure",
                "Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles reported; patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk; administer product with patient in upright position",
                "May bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy; administer other oral medications at least 3 hours before or 3 hours after therapy; patients with gastroparesis may require a 6 hour separation"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "meloxicam",
            "description": {
                "common": "meloxicam increases toxicity of sodium polystyrene sulfonate by Other (see comment). Contraindicated. \nComment: Cases of intestinal necrosis (possibly fatal) described with concomitant sorbitol and sodium polystyrene sulfonate; due to sorbitol in meloxicam oral suspension, coadministration is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sorbitol",
            "description": {
                "common": "sodium polystyrene sulfonate, sorbitol. Mechanism: unknown. Avoid or Use Alternate Drug. Combination implicated in cases of colonic necrosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "sodium polystyrene sulfonate and deflazacort both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of magnesium sulfate by decreasing renal clearance. Use Caution/Monitor. Risk of seizure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/?magnesium sulfate/potassium chloride",
            "description": {
                "common": "sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of sodium polystyrene sulfonate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate",
            "description": {
                "common": "sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of sodium polystyrene sulfonate by Other (see comment). Use Caution/Monitor. \nComment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol",
            "description": {
                "common": "sodium polystyrene sulfonate and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium carbonate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium chloride by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium citrate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of calcium gluconate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "sodium polystyrene sulfonate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lithium",
            "description": {
                "common": "sodium polystyrene sulfonate decreases levels of lithium by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of magnesium chloride by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of magnesium citrate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "sodium polystyrene sulfonate increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "GI disturbance",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Hypokalemia",
            "percent": null
        },
        {
            "name": "Hypocalcemia",
            "percent": null
        },
        {
            "name": "Hypomagnesemia",
            "percent": null
        },
        {
            "name": "Sodium retention",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "GI concretions",
            "percent": null
        },
        {
            "name": "bezoars",
            "percent": null
        },
        {
            "name": "after oral use",
            "percent": null
        },
        {
            "name": "GI tract ulceration or necrosis",
            "percent": null
        },
        {
            "name": "which could lead to perforation",
            "percent": null
        },
        {
            "name": "Fecal impaction after rectal administration",
            "percent": null
        },
        {
            "name": "especially in children",
            "percent": null
        },
        {
            "name": "Acute bronchitis or bronchopneumonia associated with inhalation of polystyrene particles",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Intestinal necrosis",
            "percent": null
        },
        {
            "name": "Aspiration",
            "percent": null
        }
    ]
}